Introduction
============

Migraine is a common, disabling neurological disorder that affects up to 12% of the world's population.[@b1-ndt-12-1779] Migraine starts in childhood and affects quality of life for many years.[@b2-ndt-12-1779],[@b3-ndt-12-1779] Two main types of migraine, migraine with aura (MA) and migraine without aura (MO), have been defined by the International Headache Society.[@b4-ndt-12-1779] The pathophysiological mechanisms that underlie migraine are complex and not yet fully clarified. Advances in technology have informed us about the significance to migraine of events such as cortical spreading depression (CSD) and activation of the trigeminovascular system and its constituent neuropeptides, as well as the importance of neuronal and glial ion channels and transporters that contribute to the putative cortical excitatory/inhibitory imbalance that renders migraineurs susceptible to an attack.[@b5-ndt-12-1779] On the other hand, although several compounds (eg, calcitonin gene-related peptide, sex hormone metabolism, glutamate, and serotonin) have been implicated in migraine pathophysiology, our understanding of the biochemistry of migraine is still limited.[@b5-ndt-12-1779]--[@b7-ndt-12-1779]

Neurotrophic factors, such as the brain-derived neurotrophic factor (*BDNF*) and nerve growth factor (*NGF*), are now emerging as important modulators of nociceptive function in adulthood.[@b8-ndt-12-1779] *BDNF* is expressed in nociceptive sensory neurons and transported anterogradely to the dorsal horn of the spinal cord, where it is located in dense core vesicles in C-fiber terminals.[@b8-ndt-12-1779] It is the most common neurotrophin and has an important role in synaptic plasticity, neurogenesis, neural growth, and differentiation.[@b9-ndt-12-1779] Several studies pointed to the specific role of the *BDNF* system in migraine. Martins et al reported that a strong support for decreased serum *BDNF* levels in chronic migraine patients.[@b10-ndt-12-1779] Migraineurs have also been found to have a significant decrease in levels of *BDNF* in platelets compared with controls.[@b11-ndt-12-1779] In addition, the *BDNF* transcripts for polymorphism have been linked with migraine in an Australian population.[@b12-ndt-12-1779] However, *BNDF* polymorphisms in Turkish populations have not yet been evaluated.

*NGF* is widely expressed in the limbic system of the central nervous system and is thought to be involved in mood and cognition.[@b13-ndt-12-1779] It plays an important role in neuronal survival, neuroplasticity, and learning, which is essential for responding to stress.[@b14-ndt-12-1779] Also, it is known to be released by several cell types in response to tissue inflammation, and it induces hyperalgesia.[@b15-ndt-12-1779] On the other hand, peripheral *NGF* is thought to contribute to the sensitization of nociceptors. Blandini et al[@b11-ndt-12-1779] showed that a reduction of platelet *NGF* was observed in migraine sufferers.

Recently, there has been increased interest into the possible association between gene polymorphisms and the risk for migraine. The *BDNF* and *NGF* gene single-nucleotide polymorphisms (SNPs) have been associated with a number of neuropsychiatric disorders.[@b16-ndt-12-1779]--[@b20-ndt-12-1779] Moreover, while a few studies found no evidence of the rs6265 polymorphism in *BDNF* being associated with migraine susceptibility, the rs2049046 in the *BDNF* gene was observed as being associated with migraine.[@b12-ndt-12-1779],[@b21-ndt-12-1779],[@b22-ndt-12-1779] However, no data are available for *NGF* gene polymorphisms in migraine disease. We hypothesized that polymorphisms in the *BDNF* and *NGF* genes may contribute to susceptibility to migraine disease. The aims of this study were 1) to further explore a possible role of *BDNF* gene polymorphisms in migraine susceptibility in a Turkish population and 2) to study, for the first time, *NGF* as a candidate gene. Therefore, in the present study, we investigated nine polymorphisms in the *BDNF* and *NGF* genes in an adult Turkish population with migraine with/without aura and healthy controls.

Materials and methods
=====================

Study samples
-------------

We included two main groups as study and control groups in the present study. The study group consisted of 288 unselected and unrelated patients with migraine. All migraine patients, who were registered at the outpatient clinic of the Department of Neurology at Dicle University Medical Faculty and Diyarbakır Education and Research Hospital in Diyarbakır, Turkey, between January 2014 and January 2016, were included in this study. Migraine was diagnosed according to the International Headache Society criteria.[@b4-ndt-12-1779] Patients with obesity (body mass index \>30 kg/m^2^), diabetes, and other neurologic or psychiatric disorders were excluded from this study. The control group consisted of 288 healthy volunteers who applied to the other outpatient clinics at Dicle University. A complete medical history was recorded, and they were examined. The controls were unrelated to the patients, and they had no clinical evidence of migraine, no history of migraine, and no family history of migraine or other neurological and psychiatric diseases. In addition, they had no history of diabetes mellitus, hypertension, obesity (body mass index \>30 kg/m^2^), or organic or genetic disorders. The mean age, sex, and ethnicity of the control group were matched with the study group. All participants were of Turkish origin, from the same geographical area (southeastern region of Turkey), particularly around Diyarbakır. The migraine patients were assigned to two subgroups, MA and MO. This case--control study was approved by the Ethics Committee of Dicle University, Medical Faculty, and each subject provided written informed consent.

DNA isolation and genotyping
----------------------------

Whole-blood samples (200 µL) were taken into ethylene-diaminetetraacetic acid-treated tubes, and genomic DNA was isolated using a commercially available kit according to the manufacturer's instructions (QIAamp DNA Mini Kit, Qiagen, Hilden, Germany). The DNA concentration was determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA), and samples were stored at −20°C until a polymerase chain reaction (PCR) was performed. In total, nine SNPs within the *NGF* and *BDNF* genes were selected based on their functionality, according to the National Center of Biotechnology Information databases ([www.ncbi.nlm.nih.gov/projects/SNP/](http://www.ncbi.nlm.nih.gov/projects/SNP/)), the International HapMap Project database ([www.hapmap.org](http://www.hapmap.org)), and a review of the literature for neuropsychiatric disorders.[@b12-ndt-12-1779],[@b16-ndt-12-1779],[@b18-ndt-12-1779]--[@b22-ndt-12-1779] Genotyping was carried out using Taq-Man 5′-exonuclease allelic discrimination assays (Thermo Fisher Scientific) and the StepOnePlus Real-Time PCR system (Thermo Fisher Scientific) for the following variants: rs6265(G/A), rs8192466(C/T), rs925946(G/T), rs2049046(A/T), and rs12273363(T/C) in the *BDNF* gene, and rs6330(C/T), rs11466112(C/T), rs11102930(C/A), and rs4839435(G/A) in the *NGF* gene. PCR conditions were 60°C for 30 seconds and 95°C for 10 minutes, followed by 40 cycles of 15 seconds at 95°C for and 1 minute at 60°C. Finally, 60°C for 30 seconds was applied for post-PCR reading. The fluorescent signal was detected at the pre-PCR, amplification (at the end of each cycle), and post-PCR reading steps.

Statistical analysis
--------------------

The distributions of the genotype and polymorphism between migraine and control groups were compared by using chi-square (*χ*^2^) or Fisher exact tests. For the age variable, which is a continuous value, the normality test was conducted using the Kolmogorov--Smirnov test. The age variable was compared between the two groups using Student's *t*-test. Two-tailed tests were used unless otherwise stated. The goodness of fit *χ*^2^ test was used to assess deviations from the Hardy--Weinberg equilibrium in the control group. The data were given as mean ± standard deviation or frequency. A *P*-value of less than 0.05 was considered to show a statistically significant result. Bonferroni corrections were applied to each test to adjust for multiple testing. Since the *BDNF* and *NGF* polymorphisms have three genotypes, the Bonferroni corrections were made for each of the three tests conducted, with the significance criterion of *P*\<0.017 (*P*=0.05/3). Odds ratios (ORs) and 95% confidence intervals (CIs) were also calculated. Statistical analyses were performed with SPSS 15.0 (SPSS Inc., Chicago, IL, USA).

Power analysis
--------------

For tests used in allele and genotype analysis, post hoc computation of the achieved power of the sample was calculated with G\*Power software, version 3.1.9 (Heinrich-Heine-Universität, Düsseldorf, Germany).[@b23-ndt-12-1779] With the current sample size, the achieved power of the study was between 0.66 and 0.78 for the *df* =2 (*χ*^2^=7.242) and *df* =1 (*χ*^2^=7.382) tests, respectively.

Results
=======

Clinical characteristics of the subjects
----------------------------------------

The study group consisted of 288 subjects (137 males, 151 females) with a mean age of 31.26±10.28 years, and the control group consisted of 288 healthy subjects (133 males, 155 females) with a mean age of 31.53±8.92 years. There was no significant difference in age or sex between the groups (*P*=0.729, *P*=0.738, respectively). In addition, the number of patients who had MA was 112 (38.9%), and the number who had MO was 176 (61.1%). The demographic characteristics of the groups are listed in [Table 1](#t1-ndt-12-1779){ref-type="table"}.

Comparison of the genotype and allele distributions
---------------------------------------------------

The genotype distributions of four SNPs in the *BDNF* gene and three SNPs in the *NGF* gene in the controls and in the patients followed Hardy--Weinberg equilibrium ([Table 2](#t2-ndt-12-1779){ref-type="table"}). The allelic and genotypic distributions of the analyzed SNPs are listed in [Tables 3](#t3-ndt-12-1779){ref-type="table"} and [4](#t4-ndt-12-1779){ref-type="table"}. No significant difference in genotypic and allelic distribution was observed in these SNPs in the *BDNF* and *NGF* genes between migraine patients and healthy controls. However, the allelic distribution of rs6265 in the *BDNF* gene showed a borderline significant difference between migraine cases and healthy controls (*P*=0.049; ORs \[95% CIs\] =0.723 \[0.523--0.999\]). In the migraine patients, 100 (17.4%) had the minor A allele and 476 (82.6%) had the G allele; in the control subjects, 76 (13.2%) had the A allele and 500 (86.8%) had the G allele for the *BDNF* rs6265 polymorphism. The frequency of the minor A allele of rs6265 was higher in the patients compared with the healthy controls.

Migraine patients were divided into two subgroups: the first group was the MA group (n=112) and the second group was the MO group (n=176). A significant association was detected between *NGF* rs6330 polymorphism and aura. A total of 90 MA patients and 172 MO patients were successfully genotyped for rs6330 polymorphism. Regarding the rs6330 polymorphism, 32 (35.6%) were identified with the CC genotype, 41 (45.6%) with the CT genotype, and 17 (18.9%) with the rare TT genotype from patients with MA. Among the 172 subjects in the MO group, 83 (48.3%) were identified with the CC genotype, 73 (42.4%) with the CT genotype, and 16 (9.3%) with the rare TT genotype. The rare TT genotype of rs6330 was significantly higher in the patients with aura compared to the patients without aura (*χ*^2^=6.613, *df* =2, *P*=0.036). However, the significance was not maintained after Bonferroni adjustment (*P*\<0.017). In the analysis of allele distributions, the frequency of the C allele was 105 (58.3%) and 239 (69.5%) in the MA and MO groups, respectively. The frequency of the rare T allele was 75 (41.7%) and 105 (30.5%) in the MA and MO groups, respectively. A significant difference in allele frequencies of rs6330 polymorphism was observed between the MA and MO groups (*χ*^2^=6.506, *P*=0.011, ORs \[95% CIs\] =1.626 \[1.117--2.365\]). The rare T allele was more frequent in the MA group. It was shown that migraine patients with the T allele had a 1.62-fold higher risk of developing aura (ORs \[95% CIs\] =1.626 \[1.117--2.365\]). Furthermore, we compared the differences between the MA group and healthy controls in all analyzed polymorphisms, and only the rs6330 variant was observed to be significantly associated with MA for both allelic (*χ*^2^=7.382, *P*=0.007) and genotypic (*χ*^2^=7.242, *P*=0.026) frequency distributions ([Tables 3](#t3-ndt-12-1779){ref-type="table"} and [4](#t4-ndt-12-1779){ref-type="table"}). However, the significance was not maintained after Bonferroni adjustment in the genotype distribution of rs63330. Meanwhile, the T allele of rs6330 was more frequent in patients with aura than in healthy subjects (*P*=0.007, ORs \[95% CIs\] =1.610 \[1.140--2.274\]), suggesting an association with increased susceptibility to aura in migraine patients. Additionally, there was no statistically significant difference between MO and healthy controls for the genotype and allele distributions of all studied polymorphisms. On the other hand, only the CC genotype was observed in all patients and controls for the *BDNF* rs8192466(C/T) and *NGF* rs11466112(C/T) polymorphisms, while the CT and TT genotypes were not observed in all participants.

Discussion
==========

In this study, the relationship between migraine disease and polymorphisms in the *BDNF* and *NGF* genes was investigated in migraine patients and healthy controls. The functional *BDNF* rs6265 (p.Val66Met) polymorphism has a borderline association with migraine in the Turkish population. Also, we found a significant association between *NGF* rs6330 polymorphism and aura.

The *BDNF* concentrations and the various polymorphisms in the *BDNF* gene have been associated with a wide array of diseases and conditions, reflecting their involvement in neuronal function. A few studies have previously evaluated associations between *BDNF* and developing migraine risk. The studies have reported that migraine patients have elevated *BDNF* levels in serum during migraine attacks[@b24-ndt-12-1779] or decreased *BDNF* levels in platelets, possibly attributable to platelet activation during migraine attacks with immediate release of *BDNF* when compared with healthy controls.[@b11-ndt-12-1779] To date, three studies have investigated whether the various *BDNF* polymorphisms, including rs6265, are related to migraine risk. Marziniak et al[@b21-ndt-12-1779] have shown that the functional rs6265 polymorphism in *BDNF* is not associated with migraine in a German population. Similar to the two studies by Sutherland et al[@b12-ndt-12-1779] in an Australian population and Lemos et al[@b22-ndt-12-1779] in a Spanish cohort, they found no evidence of rs6265 in *BDNF* as a risk factor for migraine, nor the migraine subtypes MO or MA. Moreover, they found that rs2049046 polymorphism, which resides at the 5′ end of one of the *BDNF* transcripts, may be associated with migraine. However, we did not detect any association between rs2049046 polymorphism and migraine in our cohort. The rs6265 (c.196G/A) polymorphism is the most extensively studied SNP in the *BDNF* gene. This polymorphism results in the substitution of a valine (Val) amino acid for a methionine (Met) amino acid residue at position 66 (p.Val66Met) that is known to affect the function of the protein. The polymorphism modifies the intracellular packaging of pro-BDNF and impacts on activity-dependent secretion of mature BDNF.[@b25-ndt-12-1779] The rs6265 is within the pro-protein region of *BDNF* and affects the level of mature proteins. Thus, we found a slightly higher prevalence of the Met allele (minor A allele) in the *BDNF* gene in migraine patients in our Turkish population. This result indicated that there is a borderline association between the rs6265\*A allele and migraine (*P*=0.49), and this should be considered cautiously. Our current finding must be confirmed by future studies performed with larger samples.

The *NGF* gene is located on chromosome 1p13.1, spanning approximately 52.3 kb and including three exons.[@b17-ndt-12-1779] It was associated with peripheral nociception, primarily in inflammation, acting in TRPV1 activation.[@b26-ndt-12-1779] The TRPV1 receptor conducts pain sensation to the trigeminal nucleus caudalis via the trigeminal ganglion, which implies possible contribution of the TRPV1 receptor to migraine headache.[@b27-ndt-12-1779] In the literature, there is a limited number of studies evaluating the relationship between *NGF* concentration and migraine. Sarchielli et al[@b28-ndt-12-1779] found increased *NGF* levels in cerebrospinal fluid in patients with chronic migraine, but this finding was not specific for migraine, as it was also reported in primary fibromyalgia syndrome. Blandini et al[@b11-ndt-12-1779] showed that a significant reduction was observed in platelet *NGF* levels of MA and MO patients compared with healthy controls. *NGF* variants may regulate mood and therapeutic response through modulating neuroplasticity. A nonsynonymous polymorphism of the *NGF* gene, rs6330 (c.104C\>T, GCC\>GTC, p.Ala35Val), leads to an alanine-to-valine substitution at amino acid position 35 and is suggested to influence the intracellular processing and secretion of the *NGF* protein.[@b17-ndt-12-1779] Also, Zakharyan et al[@b16-ndt-12-1779] demonstrated that the rs6330 genotypes affected the plasma levels of NGF. It has also been shown that the rs6330 SNP is associated with a response to cognitive behavioral therapy in pediatric patients with anxiety disorders, executive dysfunction in patients with Alzheimer's disease, affective disorders, and schizophrenia.[@b16-ndt-12-1779],[@b18-ndt-12-1779],[@b29-ndt-12-1779] However, a study of the association between migraine and the rs6330 polymorphism in the *NGF* gene was for the first time performed in the present study. We found significant association with *NGF* rs6330 polymorphism and MA. The aura is an integral feature of the migraine attack in this subset of patients, but the nature of this phenomenon and its role in migraine pathophysiology remain incompletely understood. CSD is a slowly propagating wave of neuronal and glial depolarization that can activate trigeminal nociceptors in brain tissue, and it is most probably the underlying mechanism of aura.[@b30-ndt-12-1779] Upregulation of neurotrophic cascades has been previously associated with CSD.[@b31-ndt-12-1779] Furthermore, the genes of some neurotrophins have been found to be differentially expressed after CSD in the rat cortex, such as the *BDNF* gene and the neurotrophic tyrosine kinase receptor gene.[@b32-ndt-12-1779] Our findings suggest that an important member of the neurotrophin family is *NGF*, which could be involved in pathogenesis in the aura component of MA. We suggest that there is also a need for studies to clarify the importance of the *NGF* in aura pathophysiology.

This report has several limitations, such as a small sample size. The statistical power of the comparison of genotypes and allele frequencies among groups was below 0.78. All these statistical powers were calculated according to the obtained results. The second limitation is the imbalance in the number of patients with MA and MO in the patient group. Third, we did not measure serum levels of *BDNF* and *NGF* in the case and control groups. Finally, a limited number of polymorphisms in the *NGF* and *BDNF* genes was genotyped in the present study.

In conclusion, this is the first clinical study to evaluate the association between *BDNF* and *NGF* polymorphisms in migraine patients compared to those of healthy controls. We found that the minor T allele of rs6330 in *NGF* was significantly associated with MA in a Turkish case--control population. Our findings indicate that the *NGF* rs6330\*T allele could play a potential role in susceptibility to aura in migraine disease. Larger sample examinations across various ethnic groups will further clarify the role of polymorphisms in *BDNF* and *NGF* in the etiology of migraine disease.
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###### 

Demographic characteristics of study participants

  Parameters               Migraine patients (n=288)   Healthy controls (n=288)   *P*-value
  ------------------------ --------------------------- -------------------------- -----------
  Age, years (mean ± SD)   31.26±10.28                 31.53±8.92                 0.729
  Sex                                                                             
   Female n, (%)           151 (52.4)                  155 (53.8)                 0.738
   Male n, (%)             137 (47.6)                  133 (46.2)                 
  Migraine types                                                                  
   MA n, (%)               112 (38.9)                                             
   MO n, (%)               176 (61.1)                                             

**Abbreviations:** MA, migraine with aura; MO, migraine without aura; SD, standard deviation.

###### 

Hardy--Weinberg law in studied SNPs in the groups

  Gene     SNP          Migraine patients   Healthy controls           
  -------- ------------ ------------------- ------------------ ------- -------
  *BDNF*   rs6265       0.078               0.779              0.001   0.994
           rs925946     0.062               0.803              0.497   0.481
           rs2049046    0.151               0.697              3.544   0.059
           rs12273363   1.071               0.301              0.237   0.626
  *NGF*    rs6330       0.326               0.568              0.249   0.617
           rs11102930   0.921               0.337              0.143   0.704
           rs4839435    0.299               0.584              0.109   0.741

**Abbreviations:** *χ*^2^, chi-square; SNP, single-nucleotide polymorphism.

###### 

Distribution of the genotype and allele of SNPs in *BDNF* and *NGF* genes in all groups

  Gene     rs number         Group      N     Genotypes (N, freq)                              Alleles (N, freq)   
  -------- ----------------- ---------- ----- --------------------- ------------- ------------ ------------------- -------------
  *BDNF*   rs6265(G/A)                        GG                    GA            AA           G                   A
                             Migraine   288   196 (0.681)           84 (0.292)    8 (0.028)    476 (0.826)         100 (0.174)
                             MA         112   75 (0.670)            35 (0.312)    2 (0.018)    185 (0.826)         39 (0.174)
                             MO         176   121 (0.688)           49 (0.278)    6 (0.034)    291 (0.827)         61 (0.173)
                             HC         288   217 (0.753)           66 (0.229)    5 (0.017)    500 (0.868)         76 (0.132)
  *BDNF*   rs925946(G/T)                      GG                    GT            TT           G                   T
                             Migraine   288   183 (0.635)           94 (0.326)    11 (0.038)   460 (0.799)         116 (0.201)
                             MA         112   68 (0.607)            41 (0.366)    3 (0.027)    177 (0.790)         47 (0.210)
                             MO         176   115 (0.653)           53 (0.301)    8 (0.045)    283 (0.804)         69 (0.196)
                             HC         288   174 (0.604)           97 (0.337)    17 (0.059)   445 (0.773)         131 (0.227)
  *BDNF*   rs2049046(A/T)                     AA                    AT            TT           A                   T
                             Migraine   288   64 (0.222)            147 (0.510)   77 (0.267)   275 (0.477)         301 (0.523)
                             MA         112   26 (0.232)            60 (0.536)    26 (0.232)   112 (0.500)         112 (0.500)
                             MO         176   38 (0.216)            87 (0.494)    51 (0.290)   163 (0.463)         189 (0.537)
                             HC         288   82 (0.285)            128 (0.444)   78 (0.271)   292 (0.507)         284 (0.493)
  *BDNF*   rs12273363(T/C)                    TT                    TC            CC           T                   C
                             Migraine   288   224 (0.778)           62 (0.215)    2 (0.007)    510 (0.885)         66 (0.115)
                             MA         112   84 (0.750)            28 (0.250)    0 (0.000)    196 (0.875)         28 (0.125)
                             MO         176   140 (0.795)           34 (0.193)    2 (0.011)    314 (0.892)         38 (0.108)
                             HC         288   212 (0.736)           69 (0.240)    7 (0.024)    493 (0.856)         83 (0.144)
  *NGF*    rs6330(C/T)                        CC                    CT            TT           C                   T
                             Migraine   262   115 (0.439)           114 (0.435)   33 (0.126)   344 (0.656)         180 (0.344)
                             MA         90    32 (0.356)            41 (0.456)    17 (0.189)   105 (0.583)         75 (0.417)
                             MO         172   83 (0.483)            73 (0.424)    16 (0.093)   239 (0.695)         105 (0.305)
                             HC         288   140 (0.486)           119 (0.413)   29 (0.101)   399 (0.693)         177 (0.307)
  *NGF*    rs11102930(C/A)                    CC                    CA            AA           C                   A
                             Migraine   281   75 (0.267)            148 (0.527)   58 (0.206)   298 (0.530)         264 (0.470)
                             MA         107   31 (0.290)            53 (0.495)    23 (0.215)   115 (0.537)         99 (0.463)
                             MO         174   44 (0.253)            95 (0.546)    35 (0.201)   183 (0.526)         165 (0.474)
                             HC         288   76 (0.264)            147 (0.510)   65 (0.226)   299 (0.519)         277 (0.481)
  *NGF*    rs4839435(G/A)                     GG                    GA            AA           G                   A
                             Migraine   288   270 (0.938)           18 (0.062)    0 (0.0)      558 (0.969)         18 (0.031)
                             MA         112   105 (0.938)           7 (0.062)     0 (0.0)      217 (0.969)         7 (0.031)
                             MO         176   165 (0.938)           11 (0.062)    0 (0.0)      341 (0.969)         11 (0.031)
                             HC         288   277 (0.962)           11 (0.038)    0 (0.0)      565 (0.981)         11 (0.019)

**Abbreviations:** BDNF, brain-derived neurotrophic factor; freq, frequency; HC, healthy control; MA, migraine with aura; MO, migraine without aura; NGF, nerve growth factor; SNP, single-nucleotide polymorphism.

###### 

Chi-square analysis of the allelic and genotypic frequencies in all migraine groups and controls for all studied SNPs

  Subjects          Genotypes   Alleles                                          
  ----------------- ----------- --------- -------------- ------- --- ----------- ----------------------
  BDNF rs6265                                                                    
   Migraine vs HC   3.920       2         0.141          3.862   1   **0.049**   0.723 (0.523--0.999)
   MA vs HC         2.995       2         0.223          2.329   1   0.127       0.721 (0.473--1.099)
   MO vs HC         3.011       2         0.221          2.968   1   0.085       0.725 (0.502--1.046)
   MA vs MO         0.954       2         0.621          0.001   1   0.980       1.006 (0.646--1.565)
  BDNF rs925946                                                                  
   Migraine vs HC   1.559       2         0.458          1.159   1   0.281       1.167 (0.881--1.547)
   MA vs HC         1.877       2         0.391          0.289   1   0.591       1.108 (0.761--1.614)
   MO vs HC         1.228       2         0.541          1.275   1   0.259       1.207 (0.870--1.675)
   MA vs MO         1.739       2         0.419          0.162   1   0.687       1.089 (0.718--1.650)
  BDNF rs2049046                                                                 
   Migraine vs HC   3.538       2         0.170          1.003   1   0.316       1.125 (0.893--1.418)
   MA vs HC         2.719       2         0.256          0.031   1   0.859       1.028 (0.755--1.399)
   MO vs HC         2.727       2         0.255          1.683   1   0.194       1.192 (0.914--1.555)
   MA vs MO         1.161       2         0.559          0.748   1   0.387       1.159 (0.829--1.621)
  BDNF rs12273363                                                                
   Migraine vs HC   3.482       2         0.175          2.227   1   0.135       0.768 (0.544--1.086)
   MA vs HC         2.779       2         0.249          0.492   1   0.483       0.848 (0.536--1.343)
   MO vs HC         2.510       2         0.285          2.517   1   0.113       0.719 (0.477--1.082)
   MA vs MO         2.481       2         0.289          0.392   1   0.531       0.847 (0.504--1.424)
  NGF rs6330                                                                     
   Migraine vs HC   1.591       2         0.451          1.642   1   0.200       1.179 (0.916--1.518)
   MA vs HC         7.242       2         **0.026**^a^   7.382   1   **0.007**   1.610 (1.140--2.274)
   MO vs HC         0.100       2         0.951          0.004   1   0.948       0.990 (0.741--1.323)
   MA vs MO         6.613       2         **0.036**^a^   6.506   1   **0.011**   1.626 (1.117--2.365)
  NGF rs11102930                                                                 
   Migraine vs HC   0.322       2         0.851          0.141   1   0.706       1.045 (0.829--1.319)
   MA vs HC         0.267       2         0.874          0.209   1   0.647       1.076 (0.785--1.473)
   MO vs HC         0.614       2         0.735          0.039   1   0.842       1.027 (0.787--1.341)
   MA vs MO         0.721       2         0.697          0.071   1   0.790       0.954 (0.678--1.343)
  NGF rs4839435                                                                  
   Migraine vs HC   1.779       1         0.182          1.733   1   0.188       1.657 (0.775--3.539)
   MA vs HC         1.108       1         0.292          1.083   1   0.298       1.657 (0.634--4.329)
   MO vs HC         1.429       1         0.232          1.394   1   0.237       1.657 (0.711--3.863)
   MA vs MO         0.000       1         1.000          0.000   1   1.000       1.000 (0.382--2.619)

**Notes:** Statistically significant results are given in bold. ^a^The significance was not maintained after Bonferroni adjustment (*P*corrected,0.017 \[0.05/3\]).

**Abbreviations:** BDNF, brain-derived neurotrophic factor; *χ*^2^, chi-square; *df*, degrees of freedom; HC, healthy control; MA, migraine with aura; MO, migraine without aura; NGF, nerve growth factor; ORs (95% CIs), odds ratios (95% confidence intervals); SNPs, single-nucleotide polymorphisms.
